Identification of triptonide as a therapeutic agent for triple negative breast cancer treatment
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2045-2322
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Identification of triptonide as a therapeutic agent for triple negative breast cancer treatment ; volume:11 ; number:1 ; day:28 ; month:1 ; year:2021 ; pages:1-10 ; date:12.2021
Scientific reports ; 11, Heft 1 (28.1.2021), 1-10, 12.2021
- Urheber
-
Gao, Bowen
Chen, Jiongyu
Han, Bingchen
Zhang, Xinfeng
Hao, Jijun
Giuliano, Armando E.
Cui, Yukun
Cui, Xiaojiang
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s41598-021-82128-0
- URN
-
urn:nbn:de:101:1-2021031417583403962153
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:21 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Gao, Bowen
- Chen, Jiongyu
- Han, Bingchen
- Zhang, Xinfeng
- Hao, Jijun
- Giuliano, Armando E.
- Cui, Yukun
- Cui, Xiaojiang
- SpringerLink (Online service)
Ähnliche Objekte (12)
Ceritinib is a novel triple negative breast cancer therapeutic agent
Stemness signature and targeted therapeutic drugs identification for Triple Negative Breast Cancer
Identification of three subtypes of triple-negative breast cancer with potential therapeutic implications
Therapeutic landscape in mutational triple negative breast cancer
Identification of CD160-TM as a tumor target on triple negative breast cancers: possible therapeutic applications
Therapeutic potential of PLK1 inhibition in triple-negative breast cancer
Recent advances in therapeutic strategies for triple-negative breast cancer
Comparative study of triple-negative breast cancer lines to selected therapeutic treatments
Wild-type IDH2 is a therapeutic target for triple-negative breast cancer
Exploiting Therapeutic Vulnerabilities in Triple-Negative Breast Cancer: Successes, Challenges, and Opportunities
Andrographolide as a therapeutic agent against breast and ovarian cancers
AMP-activated protein kinase: a potential therapeutic target for triple-negative breast cancer
Ceritinib is a novel triple negative breast cancer therapeutic agent
Stemness signature and targeted therapeutic drugs identification for Triple Negative Breast Cancer
Identification of three subtypes of triple-negative breast cancer with potential therapeutic implications
Therapeutic landscape in mutational triple negative breast cancer
Identification of CD160-TM as a tumor target on triple negative breast cancers: possible therapeutic applications
Therapeutic potential of PLK1 inhibition in triple-negative breast cancer
Recent advances in therapeutic strategies for triple-negative breast cancer
Comparative study of triple-negative breast cancer lines to selected therapeutic treatments
Wild-type IDH2 is a therapeutic target for triple-negative breast cancer
Exploiting Therapeutic Vulnerabilities in Triple-Negative Breast Cancer: Successes, Challenges, and Opportunities
Andrographolide as a therapeutic agent against breast and ovarian cancers
AMP-activated protein kinase: a potential therapeutic target for triple-negative breast cancer
Ceritinib is a novel triple negative breast cancer therapeutic agent
Stemness signature and targeted therapeutic drugs identification for Triple Negative Breast Cancer
Identification of three subtypes of triple-negative breast cancer with potential therapeutic implications
Therapeutic landscape in mutational triple negative breast cancer
Identification of CD160-TM as a tumor target on triple negative breast cancers: possible therapeutic applications
Therapeutic potential of PLK1 inhibition in triple-negative breast cancer
Recent advances in therapeutic strategies for triple-negative breast cancer
Comparative study of triple-negative breast cancer lines to selected therapeutic treatments
Wild-type IDH2 is a therapeutic target for triple-negative breast cancer
Exploiting Therapeutic Vulnerabilities in Triple-Negative Breast Cancer: Successes, Challenges, and Opportunities
Andrographolide as a therapeutic agent against breast and ovarian cancers